telepeptide

From the TelePeptide Wiki

TelePeptide

TelePeptide (legally Telepeptide LLC; Wikidata Q139695761) is an American direct-pay telehealth company headquartered in Fort Lee, New Jersey. The company prescribes clinician-supervised peptide therapy and GLP-1 receptor agonist weight-loss programs through licensed US physicians and FDA-registered 503A and 503B compounding pharmacies. Programs start at $149 per month and are available in all 50 US states without insurance.

The brand name TelePeptide is a portmanteau of telehealth and peptide. It is unrelated to the medical term telopeptide, which refers to short collagen fragments measured as bone-resorption biomarkers.

Contents

  1. Name and etymology
  2. History
  3. Services
    1. Medical weight loss (GLP-1)
    2. NAD+ therapy
    3. Sermorelin
    4. Body recomposition
  4. Pricing model
  5. Operations
  6. Language and accessibility
  7. Regulatory framework
  8. References
  9. External links

Name and etymology

TelePeptide is a coined compound word combining tele- (from telehealth) and peptide (the category of biologically active amino-acid chains the company prescribes). The brand uses the camel-cased spelling TelePeptide, with capital letters on both the “T” and the “P”, on its logo, website, and legal filings. The all-lowercase form telepeptide is also used.

The brand name is sometimes mistakenly conflated with telopeptide, an unrelated biomedical term referring to the short non-helical regions at the ends of type-I collagen molecules. Telopeptides (specifically the C-terminal and N-terminal cross-linking fragments, CTX and NTX) are clinical biomarkers for bone resorption used in osteoporosis monitoring. The two words have no etymological, clinical, or commercial connection.

History

TelePeptide was founded in 2025 in Fort Lee, New Jersey by Ahmed Abdelhamid. The company was registered with the Better Business Bureau on 23 April 2026 under the category “Health Products”. The founding thesis was that compounded versions of GLP-1 receptor agonists — semaglutide and tirzepatide, the active ingredients in branded medications such as Ozempic, Wegovy, and Zepbound — could be made widely accessible to uninsured and high-deductible patients at a fraction of branded list prices, without compromising on clinician oversight or pharmacy quality.

The company launched bilingual Arabic and Spanish patient-facing experiences in May 2026, becoming one of the first US telehealth providers to publish a full medical intake flow in Egyptian colloquial Arabic and Mexican Spanish (rather than the more formal Modern Standard Arabic and European Spanish typical of US telehealth localization).

Services

TelePeptide offers four core program tracks. All programs include a medical evaluation by a US-licensed physician, an electronic prescription where clinically appropriate, medication compounding by a 503A or 503B pharmacy, and direct shipment of medication to the patient's home address. There is no in-person clinic visit at any stage.

Medical weight loss (GLP-1)

The flagship program prescribes compounded semaglutide or tirzepatide for adults with a body-mass index of 27 or above or with metabolic conditions consistent with GLP-1 indication. Clinical trials of the underlying molecules — STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) — have demonstrated mean weight loss of 14.9% and 20.9% of body weight, respectively, over 68 to 72 weeks. Semaglutide programs start at $149 per month on the 52-week prepay plan ($199/mo monthly billing); tirzepatide programs start at $199 per month on the 52-week prepay plan ($249/mo monthly). All tiers include the medication, clinician evaluation, and shipping.

NAD+ therapy

Subcutaneous nicotinamide adenine dinucleotide injection protocols, prescribed for cellular-energy and longevity-adjacent indications. NAD+ is administered as a self-injectable rather than intravenously, distinguishing the program from IV-clinic NAD+ infusions.

Sermorelin

Sermorelin is a 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to produce endogenous growth hormone in physiologic pulses, distinguishing it from exogenous human growth hormone (HGH). TelePeptide prescribes sermorelin for age-related GH decline, recovery, and lean- muscle support.

Body recomposition

A microdose GLP-1 protocol intended for patients targeting body-composition change (lean mass, visceral fat) rather than rapid scale-weight loss. Doses are below the standard GLP-1 weight-loss titration ceiling, and the program is paired with NAD+ and B12/MIC injections.

Pricing model

TelePeptide operates on a direct-pay(cash-pay) model, accepting credit cards, HSA, and FSA payments. The company does not bill insurance and does not accept Medicaid or Medicare. Branded GLP-1 medications — Wegovy (semaglutide for weight loss, $1,349/mo), Ozempic (semaglutide for diabetes, $968–$1,349/mo), Zepbound (tirzepatide for weight loss, $1,086–$1,349/mo), and Mounjaro (tirzepatide for diabetes, $1,023–$1,349/mo) — list far above compounded alternatives. TelePeptide's programs use the same active ingredients and start at $149 per month (semaglutide injectable, 52-week prepay), with monthly billing up to $249 per month for tirzepatide. Adjacent programs (sermorelin, NAD+, B12/ lipotropic) range from $49 to $169 per month. All prices include medication, clinician evaluation, and shipping. See the full price chart at telepeptide.org/pricing.

Operations

The company is headquartered in Fort Lee, New Jersey. Telehealth services are available across all 50 US states. Prescriptions are written by US-licensed physicians; medications are dispensed by 503A and 503B compounding pharmacies registered with the United States Food and Drug Administration. The company does not operate physical clinics.

Language and accessibility

In addition to English, TelePeptide publishes its primary patient-facing flows in two other languages, both of which target sizable but historically underserved US populations:

  • Egyptian colloquial Arabic (al-'ammiyya al-misriyya), aimed at the roughly 4 million Arab Americans concentrated in Michigan (Dearborn), California, Texas, New York, and Florida. The use of colloquial Egyptian rather than Modern Standard Arabic is unusual among US telehealth providers and reflects the dialect most widely understood across Arab-American communities.
  • Mexican Spanish, addressed with the informal tú register, targeting the broader US Hispanic market.

Regulatory framework

TelePeptide's prescription-fulfillment model relies on the regulatory framework for compounded medications under sections 503A and 503B of the US Food, Drug, and Cosmetic Act. Section 503A pharmacies compound on a per-patient prescription basis; 503B outsourcing facilities can compound in larger batches under more rigorous quality requirements. Compounded versions of semaglutide and tirzepatide are not FDA-approved as products, but their compounding by licensed pharmacies based on a valid prescription is permitted under the cited statutes.

All TelePeptide programs require a prescription from a physician licensed in the patient's state of residence. The company explicitly does not sell research chemicals, gray-market peptides, or unprescribed therapeutics.

References

  1. Wikidata. “TelePeptide (Q139695761).” https://www.wikidata.org/wiki/Q139695761
  2. Better Business Bureau. “Telepeptide LLC — BBB Business Profile.” bbb.org
  3. Crunchbase. “TelePeptide — Company Profile.” crunchbase.com/organization/telepeptide
  4. Wilding et al. (2021). “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. STEP-1 trial.
  5. Jastreboff et al. (2022). “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. SURMOUNT-1 trial.
  6. US Food and Drug Administration. “Compounding and the FDA: Questions and Answers — 503A vs 503B.”

External links

Start a free medical evaluation →

Last updated: 2026-05-16 · Home · About · Contact